Category Archives: Global News Feed

CANTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” and the “Company”) today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Wednesday, June 19, 2024 at 4:30 PM ET. The topics to be discussed include but are not limited to:

Read the original post:
Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET

13 June 2024

Read more from the original source:
Results of Annual General Meeting

Company expects to report top-line data and complete study results in Q3 2024

See more here:
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Senior R&D leader brings extensive expertise in immunology, clinical development and translational science Senior R&D leader brings extensive expertise in immunology, clinical development and translational science

See the original post here:
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, presents updated data from its Phase 1 trial of INB-100 at the European Hematology Association (EHA) 2024 Hybrid Congress.

Read this article:
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Mr. Webster brings more than 20 years of executive level experience in the life sciences industry Mr. Webster brings more than 20 years of executive level experience in the life sciences industry

The rest is here:
Beyond Air® Appoints David Webster as Chief Commercial Officer

SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Steve Krognes to its Board of Directors.

Read the rest here:
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company’s board of directors.

Read the original:
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024

Read the rest here:
Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along...

FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024.

The rest is here:
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update